美國(guó)Epitomics  www.epitomics.com
美國(guó)Epitomics公司成立于2001年9月，與加州大學(xué)舊金山分校(UCSF)及芝加哥LOYOLA大學(xué)聯(lián)手開(kāi)發(fā)出新型雜交瘤技術(shù)，擁有兔單克隆抗體（RabMabs）技術(shù)的全球?qū)＠?，是?guó)際上唯一一家擁有兔類(lèi)單抗技術(shù)的生物技術(shù)公司。目前，利用此技術(shù)開(kāi)發(fā)生產(chǎn)的高質(zhì)量兔單抗產(chǎn)品，已廣泛應(yīng)用于科研和診斷領(lǐng)域。
2012年Abcam收購(gòu)Epitomics

宜康生物技術(shù)有限公司地址： 中國(guó)浙江杭州市莫干山路1418號(hào) 
郵編： 310011
電話(huà)： 0571-88175199-總機(jī)轉(zhuǎn)
傳真： 0571-88175199-801, 0571-88174721
電郵： info@epitomics.com.cn
 
宜佰康生物技術(shù)股份有限公司住址： 臺(tái)北市陽(yáng)光街351號(hào)6樓之一
電話(huà)： (02)2627-5807
傳真： (02)2627-5979
信箱： ir@epitomics.com

Epitomics, Inc., an emerging biotechnology company, is dedicated to developing their breakthrough monoclonal antibody technology (RabMAb) for research, diagnostics and therapeutics. The Company has utilized a unique and proprietary RabMAb technology invented by scientists at Loyola University of Chicago and the University of California at San Francisco. This enabling platform produces high quality antibodies that have the potetial to be used in the broad areas of research, diagnostics and therapeutics.
Compared to currently available monoclonal antibody technology, such as mouse hybridomas, the Company's proprietary technology can generate RabMAbs more efficiently and with superior binding affinity and bioactivity in a wide variety of biological assays. The high throughput and robust nature of the technology allows for the simultaneous discovery of disease targets and potential therapeutic antibodies in the same experiments, significantly shortening the drug discovery and development cycle.
The Company aims to become the largest provider of monoclonal antibody technology through developing and commercializing their RabMAb technology and products in research, diagnostics, and therapeutics. The Company is headquartered in Burlingame, California and operates a wholly owned subsidiary in Hangzhou, the People's Republic of China.